© Shana Novak / Getty images

EQuIP – Earnings Quality Insurance Protection

An innovative non-damage business interruption cover protects biopharma and medical devices industries from losses arising from regulatory non-compliance business interruption.

EQuIP bridges a risk gap not covered in standard property insurance covers for the pharma industry

12,000,000,000
US-Dollars
Losses through manufacturer suspensions due to problems in quality exceed 12 billion US-Dollars since 2001.

Earnings Quality Insurance Protection (EQuIP) is a cutting edge solution for biopharma and medical-device companies. It mitigates the financial impact of a major interruption, bridges the liquidity gap, and protects shareholders’ value. The comprehensive and clear non-damage business interruption cover takes a flexible approach – a must when addressing the needs of a market shaped by complex supply chain dependences.

3 questions to ask yourself in the face of non-damage business interruption challenges:
  1. As my supply chain becomes more outsourced and complex, do I have business interruption risks that I can’t control and that are not covered under my traditional insurance? 

  2. Does my dependency on the regulatory compliance of third-party suppliers put my company’s results at greater risk when it comes to delivering on forecasts to shareholders

  3. Is there a risk transfer solution that can help me bridge my company’s liquidity gap when dealing with own manufacturing disruption due to GMP non-compliance?

5 reasons you should talk to us

EQuIP provides cover for suspension events due to GMP violations at your own or a critical supplier’s site that cannot be insured under standard property and business interruption programmes. Insuring all sites is not a requirement – optimise your purchase by selecting key sites based on exposures and risk profile.
Munich Re has invested considerable time and effort in researching and understanding both the complexities of pharma supply chains and the historical incidents of regulatory related suspensions across the sector. We build on the supply chain management strategies of your company to develop a solution tailored to your specific risk profile.

Get meaningful cover for financial losses arising from non-damage supply chain interruptions.

EQuIP offers scalable limits and broad cover:
  • Limits can be purchased from a low as US$10m in the aggregate up to US$150m in the aggregate
  • 24-month indemnity period including ongoing loss of market share once manufacture re-commences
  • Broad expenses coverage including specialist investigation and remediation costs, product destruction costs and recall costs
  • Indemnity can include loss of license or royalty fees where appropriate

Obtaining a quote for EQuIP is a simple and streamlined process.

  • To obtain a first pricing indications, supply a list of addresses for sites to be insured
  • For a firm quote, share more in-depth details in meetings or telephone interviews, no lengthy questionnaires necessary.
  • In some cases, we may need to visit a site pre-or post inception. 
Munich Re is committed developing solutions for the pharma industry and will continue to develop EQuIP and other tailored products to ensure they remain aligned to your risk landscape.

What EQuIP can do for you

  • Offers bespoke solutions for Global Pharma, Specialty Biotech, Medical Devices and CDMO companies
  • Grants coverage for a wide range of regulatory non-compliance based events
  • Provides limits from US$10m to US$150m
  • Covers your key owned and/or supplier sites against losses arising from production shutdown due to order of a Defined Regulatory Authority (DRA1)
  • Allows voluntary suspension of manufacture when a facility must shut down in order to remediate identified violations
  • Reimburses investigation expenses and the costs of remediating manufacturing problems at your own facility after a closure
  • Delivers protection in case of prohibition of import or sale of products in key markets
  • Demonstrates a comprehensive Risk Management approach to clients and investors
1 DRA – regulatory authorities that are covered as standard are those operating in USA, Canada, EU, Switzerland, Norway, Israel, Japan, Australia, New Zealand

A real-life event – and how EQuIP could have helped

A company was forced to initiate a nation-wide voluntary recall of one of its injectable drugs as a result of potential contamination with glass particles. Fill and finish of the product had been outsourced to a third party CDMO, whose facility received an FDA warning letter citing GMP failures in producing drugs to required specification and preventing microbial contamination

The outcome:
  • 3 million vials being recalled
  • Significant revenue impact as all sales of injectable products were suspended whilst root cause was identified and remediated
  • Another pharmaceutical company was also forced to recall products manufactured at the same CDMO facility
How EQuIP could have helped

EQuIP would have bridged the gap in lost earnings incurred by this pharmaceutical company. It would also have covered the recall costs and other extra expenses.

Your benefits in a nutshell

We understand the complexities for pharma supply chains
EQuIP offers scalable limits and broad cover
We use cookies on our websites to improve your experience as an internet user, and to optimise our online services. They comprise cookies that are required for technical purposes, and without which the website functionality could not be guaranteed. We also employ cookies to carry out statistical evaluations of the reach of our websites. These evaluations are anonymised. You can find further information on the cookies we use, and ways to object to the use of cookies for statistical evaluations, in our cookie guidelines.